G protein-coupled receptor 101Genealiases: GPCR6 · PAGH2 · PITA2
Q-omics provides the consensus-scored GPR101 profile across patient tissues and cancer cell-line models. GPR101 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, GPR101 is differentially expressed in 6, with the highest sampling consensus in HNSC. Additionally, GPR101 RNA expression shows 10,535 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LUSC, HNSC, and GBM as cancer lineages where GPR101 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GPR101 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GPR101 survival associations across molecular data types. GPR101 RNA expression shows survival associations in the most cancer types (16), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GPR101 RNA expression–survival associations across cancer types. High GPR101 expression shows unfavorable associations in LUSC, KIRC, DLBC and UCEC, but favorable associations in LGG and LIHC. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .005). Together, the overview and detailed table identify LUSC as the clearest survival context for GPR101 RNA expression.
This table summarizes GPR101 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for GPR101. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GPR101 shows lower tumor expression in HNSC, UCEC, COAD, THCA, LUAD and KICH. The HNSC box plot shows higher GPR101 RNA expression in normal versus tumor tissue (log2 FC = −0.101, t-test p = .006).
This table shows molecular features associated with GPR101 in patient tissues and cancer cell lines. In patient samples, GPR101 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, GPR101 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUSC, while CRISPR and shRNA rows add functional-dependency signals in BREAST and LARGE_INTESTINE.
